Skip to main content
CivicGate

HR 7877
Introduced Re-checks Congress.gov for new actions and updates the bill's status, and fills in any sponsors, committees, or related bills that are missing. It does not re-pull sponsors/cosponsors/committees/related — those rarely change — and it skips all work if nothing has changed upstream, so it's cheap to click.

Shane DiGiovanna Act

To require the Secretary of Health and Human Services to establish a demonstration program to test mandatory coverage of treatment for wound care for epidermolysis bullosa under the Medicaid program.

Introduced Mar 9, 2026

Latest action (Mar 17, 2026) Sponsor introductory remarks on measure. (CR H2535)

Referred to
Energy and Commerce Committee
Policy area
Health
Issues
Healthcare

Summary
  • Requires the HHS Secretary to establish a 2-year demonstration program within 1 year to test mandatory Medicaid coverage for wound care treatment related to epidermolysis bullosa.
  • The program would require state Medicaid plans to cover specific over-the-counter and prescription items including antihistamines, pain relievers, anti-inflammatory drugs, antiseptics, zinc oxide, antibiotic ointments, and wound dressings and bandages.
  • The demonstration program operates on a nationwide basis across all states.
  • The Secretary must submit a report to Congress within 1 year after the program ends, evaluating program costs, health outcomes compared to before the program, and recommendations for preventing hospitalizations related to epidermolysis bullosa.

AI-generated plain-language summary of the bill text — neutral, and may be imperfect. See the full text below for the exact wording.

Sponsor (1)
5 cosponsors

Money behind the sponsor

Top reported contributors to Greg Landsman’s campaign committee (2024 cycle) — who funds the bill’s sponsor, not a claim about this bill. Data from FEC.

  • UNIVERSITY OF CINCINNATI $22,085
  • CHAVEZ PROPERTIES LLC $19,800
  • KATZ TELLER $17,700
  • THE COUNSELING SOURCE INC $13,200
  • REMINGTON ROAD GROUP $10,925

Organizations whose employees gave the most — itemized individual contributions grouped by the donor’s reported employer (FEC Schedule A). Full finance for Greg Landsman → · Outside spending →

Actions (3)
  1. Mar 17, 2026 Sponsor introductory remarks on measure. (CR H2535)
  2. Mar 9, 2026 Referred to the House Committee on Energy and Commerce. · house
  3. Mar 9, 2026 Introduced in House

Similar bills (6)

Bills with similar text or summary — includes reintroductions across Congresses. Ranked by semantic similarity of the bill text (computed locally); a neutral discovery aid, not a claim the bills are duplicates.

  • HR 6852 — Advanced Wound Care and Regenerative Medicine Access and Reform Act · Introduced Dec 18, 2025 · Cong. 119 61%
  • S 3300 — ANCHOR Act of 2025 · Introduced Dec 2, 2025 · Cong. 119 59%
  • HR 6401 — Increasing Medication Access for Seniors Act of 2025 · Introduced Dec 3, 2025 · Cong. 119 57%
  • HR 7713 — Combating Deceptive Practices in Assistance Programs Act of 2026 · Introduced Feb 25, 2026 · Cong. 119 56%
  • HR 5844 — Harm Reduction Through Community Engagement Act of 2025 · Introduced Oct 28, 2025 · Cong. 119 56%
  • S 3551 — PROTECT for Rare Act · Introduced Dec 17, 2025 · Cong. 119 56%

Full text

IN THE HOUSE OF REPRESENTATIVES

March 9, 2026

Mr. Landsman introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL

To require the Secretary of Health and Human Services to establish a demonstration program to test mandatory coverage of treatment for wound care for epidermolysis bullosa under the Medicaid program.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the “Shane DiGiovanna Act”.

SEC. 2. DEMONSTRATION PROGRAM TO TEST MANDATORY COVERAGE OF TREATMENT FOR WOUND CARE FOR EPIDERMOLYSIS BULLOSA UNDER THE MEDICAID PROGRAM.

(a) In General.—Beginning not later than 1 year after the date of the enactment of this Act, the Secretary of Health and Human Services (in this section referred to as the “Secretary”) shall conduct a 2- year demonstration program under which items and services specified in subsection (b) furnished for the treatment of epidermolysis bullosa are required to be included as medical assistance under a State plan (or waiver of such plan) under title XIX of the Social Security Act (42 U.S.C. 1396 et seq.) for individuals described in section 1902(a)(10)(A)(i) of such Act (42 U.S.C. 1396a(a)(10)(A)(i)).

(b) Specified Items and Services.—For purposes of subsection (a), the items and services specified in this subsection are over-the- counter antihistamines, acetaminophen, nonsteroidal anti-inflammatory drugs, antiseptics, zinc oxide, antibiotic ointments, and necessary wound care supplies, including wound care dressings (inclusive of primary and secondary dressings), gauze, and bandage retainers.

(c) Scope of Demonstration.—The Secretary shall conduct the demonstration program described in subsection (a) on a nationwide basis.

(d) Study.—Not later than 1 year after the end of the demonstration program described in subsection (a), the Secretary shall submit to Congress a report on such program. Such report shall include the following:

(1) An evaluation of the effect of such program on expenditures for treatment of individuals with epidermolysis bullosa under the Medicaid program (taking into account any such treatment avoided due to such program).

(2) An analysis of health outcomes for such individuals compared to such outcomes before such program.

(3) Any recommendations relating to how to prevent hospitalizations relating to epidermolysis bullosa. <all>

Comments

Comments

Loading comments…